Luomengjia Dai
YOU?
Author Swipe
View article: Prognostic impacts of <i>RHOA G17V</i> mutation in cell‐free <scp>DNA</scp> assessed by droplet digital polymerase chain reaction in patients with angioimmunoblastic T‐cell lymphoma
Prognostic impacts of <i>RHOA G17V</i> mutation in cell‐free <span>DNA</span> assessed by droplet digital polymerase chain reaction in patients with angioimmunoblastic T‐cell lymphoma Open
View article: Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience
Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience Open
View article: Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort Open
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
View article: P592: SINGLE-CELL RNA SEQUENCING REVEALS THE SPATIAL HETEROGENEITY OF EXHAUSTED T CELLS IN BTKI-RESISTANT RICHTER TRANSFORMATION PATIENTS
P592: SINGLE-CELL RNA SEQUENCING REVEALS THE SPATIAL HETEROGENEITY OF EXHAUSTED T CELLS IN BTKI-RESISTANT RICHTER TRANSFORMATION PATIENTS Open
Topic: 5. Chronic lymphocytic leukemia and related disorders - Biology & Translational Research Background: The transformation of CLL to aggressive B-cell lymphoma (Richter transformation, RT) has remained a clinical challenge, with poor p…
View article: P607: INTEGRATING MULTI-OMICS TO REVEAL THE CLONAL EVOLUTIONARY CHARACTERISTICS IN CLL PATIENTS WITH ZANUBRUTINIB RESISTANCE
P607: INTEGRATING MULTI-OMICS TO REVEAL THE CLONAL EVOLUTIONARY CHARACTERISTICS IN CLL PATIENTS WITH ZANUBRUTINIB RESISTANCE Open
Background: The drug-resistant mechanisms of the first-generation Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, has been extensively explored in Chronic Lymphocytic Leukemia (CLL) patients. However, the resistant mechanisms of the s…
View article: Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort
Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: A prospective real-world study in Chinese cohort Open
Time-limited treatment strategies in first line treatment of chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) were comprehensively explored. Thirty-four previously untreated, young fit CLL/SLL patients who initiated iFCR r…
View article: Case report: Identification of atypical mantle cell lymphoma with CCND3 rearrangement by next-generation sequencing
Case report: Identification of atypical mantle cell lymphoma with CCND3 rearrangement by next-generation sequencing Open
The t(11;14) (q13;q32) translocation resulting in overexpression of cyclin D1 is the major oncogenic mechanism in mantle cell lymphoma (MCL). Most MCLs can be diagnosed based on morphological features, cyclin D1 expression, and IGH/CCND1 r…